UPC refuses extension of deadline for review of seizure order after refusal of service

​
July 22, 2025

Sichuan Yuanxing Rubber Co., Ltd. and China Council for the Promotion of International Trade, Automotive Sub Council

Order of 14 July 2025 (ORD_26742/2025 [1])

This article follows up on the UPC decision we previously reported here [2].

This Decision from the Local Division of the Unified Patent Court in Milan relates to EP3519207. Pirelli Tyre S.P.A. ("Pirelli"), was previously granted an order for evidential seizure of motorcycle tyres against Sichuan Yuanxing Rubber Co., Ltd. ("Sichuan") and China Council for the Promotion of International Trade, Automotive Sub Council ("CCPIT"), to be served and carried out at the "International Motorcycle Exhibition" ("EICMA") in Milan between 5 and 10 November 2024 (ORD_59754/2024 [3]). Pirelli subsequently brought proceedings on the merits against Sichuan and CCPIT, filing its statement of claim on 5 December 2024.

Sichuan requested a time extension after missing the deadline to seek a review of the order for seizure, pursuant to Rule 197.3 RoP, arguing that the order ORD_59754/2024 was not duly served.

The Court did not grant Sichuan's request, indicating that according to Italian law, Sichuan's refusal to accept the documents relating to the order amounted to valid service.

Sichuan's request

On 3 June 2025, Sichuan filed an application pursuant to Rules 9 and 300 of the RoP, requesting an extension of time in order to be able to file a request for review of Order No. 59754/2024, pursuant to Rule 197.3 of the RoP. Sichuan argued that at the time of execution of the order, service had not been effected in accordance with the procedures stated in the order: in particular, Sichuan stated they did not receive a copy of the application, its annexes and the order, either at EICMA or subsequently.

The Court stated that Sichuan's request must be classified as a request for relief under Rule 320 RoP even though it was formally submitted by the applicant as based on Rules 9 and 300 of the Rules of Procedure, since Sichuan claimed that they were unable to comply with the 30-day time limit provided for in the combined provisions of Rules 212.3 and 197.3 RoP for reasons beyond their control.

The Court mentioned the recent decision of the Court of Appeal ORD_69091/2024, relating to remedying failure to meet a time period through re-establishment pursuant to Rule 320 RoP, which allows the Court to authorise the extension of time limits under certain conditions and, in any event, within pre-set time limits. The Court explained that the decision of treating Sichuan's request as a request under Rule 320 RoP rather than under Rules 9 and 300 RoP, was reached to protect objective reasons of legal certainty, as to avoid unreasonably exposing the other party to a reopening of the time limits at a later date than their normal expiry: the existence of a specific rule in the Rules of Proceedings should take precedence over a more lenient general rule.

Decision

The Court stated that the enforcement of decisions and orders issued by the UPCA is governed by the law of the Contracting Member State where enforcement is sought, pursuant to Article 82.3 UPCA and Rule 354.1 RoP. As stated in the order for seizure dated 5 November 2024, the enforcement of ORD_59754/2024 was to take place at the EICMA Fair, in Rho, Milan, and therefore subject to Italian law.

Based on the report of service drawn up by the bailiff, Sichuan had been informed of the documents on 6 November 2024 but refused to accept them. The provision of Article 138 of the Italian Code of Civil Procedure was therefore taken to apply in the event of an attempt to serve a document: "if the addressee refuses to accept the copy, the bailiff shall record this in the report, and the service shall be deemed to have been effected in person".

The Court did not grant Sichuan's request for re-establishments of rights, further stating the stating that, under Rule 320.7 RoP, this decision cannot be appealed.

Related cases

At the same time as obtaining ORD_59754/2024 [3], Pirelli sought a preliminary injunction against Tianjin Kingtyre Group Co., Ltd. and Kingtyre Deutschland Gmbh ("Kingtyre") for the alleged infringement of EP2519412 by Kingtyre at the same exhibition (ORD_59764/2024 [4]). The Local Division of the Unified Patent Court in Milan issued a seizure order to be served on Kingtyre at EICMA between 5 and 10 November 2024.

On 5 December 2024, Pirelli brought proceedings on the merits before the Milan Local Division on the matter relating to EP2519412. Pending the outcome of the proceedings on the merits, Pirelli and Kingtyre Deutschland GmbH entered into a settlement agreement, effective as of 25 February 2025, aimed at amicably settling the dispute.

By order of 15 July, 2025, ORD_24978/2025 [5], the Court acknowledged the settlement agreement concluded on 25 February 2025 between Pirelli and Kingtyre Deutschland Gmbh and suspended the litigation between Pirelli Tianjin Kingtyre Group Co., Ltd.. The settlement agreement was published in redacted form together with this decision, but the Court ordered the unredacted version of the settlement remain confidential. The Court also ordered the reimbursement of 30% of the total court fees to Pirelli, departing from the usual 60% (Rule 370.9(c) RoP) on the ground that there were two defendants.

[1] https://www.unified-patent-court.org/en/node/136370

[2] https://eip.com/uk/latest/article/upc_grants_two_orders_to_seize_suspected_infringing_motorcycle_tyres/

[3] https://www.unified-patent-court.org/en/node/1293

[4] https://www.unified-patent-court.org/en/node/1294

[5] https://www.unified-patent-court.org/en/node/136393

The Latest Thought Leadership pieces in the Content Hub

UPC grants ‘in absentia’ permanent injunction on agricultural tool
July 21, 2025
Maschio Gaspardo S.p.A. v Spiridonakis Bros GP (UPC_CFI_513/2024 relating to EP1998604) Order of 25 June 2025 (ORD_17812/2025 [1]) This Decision from the Central Division of the Unified Patent Court...
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​